Overview

Semaglutide in Treatment of Obesity

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.

Phase:

PHASE3

Details

Lead Sponsor:

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Treatments:

semaglutide